eQTLGen Consortium Data accompanies the manuscript: link to biorxv (TBA) For further questions, contact the corresponding author: Lude Franke, lude@ludesign.nl ./cis-eqtl: 10.5M signicant (FDR < 0.05) cis-eQTLs ./trans-eqtl: 60K significant (FDR < 0.05) trans-eQTLs ./eqts: 18K signicicant (FDR < 0.05) eQTS ./replicaton: Replication analyses of trans-eQTLs in several purified cell types, iPSC cells and GTEx postmortem tissues. The goal of the eQTLGen consortium is to identify the downstream consequences of common genetic variation on gene expression levels with high precision and resolution. Such effects, or expression quantitative trait loci (eQTL) can be divided into local and distal effects, or cis-eQTL and trans-eQTL. Additionally, the consortium has also focused on identifying the effects of polygenic risk on gene expression (expression quantitative trait score; eQTS). The effect sizes of especially eQTS and trans-eQTLs can be rather small. Therefore, to identify such effects with high confidence, the consortium is gathering cohorts from across the world that have both genotype and gene expression data available, to consequently perform a meta-analysis. Since blood is the tissue most commonly sampled in population-based cohorts, the consortium has mainly focused on that tissue, but other tissues may be added in the future. As of 2018, supplied summary statistic level data has been combined from 37 datasets, and meta-analysis has identified >10 million cis-eQTL, >70,000 trans-eQTL, and >18,000 eQTS. The 2018 release of the trans-eQTL results have focused on ~10,000 disease- and trait-associated variants. Future releases will also include trans-eQTLs that have been ascertained genome-wide.